These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 24712563)

  • 1. Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease.
    Idorn T; Knop FK; Jørgensen MB; Christensen M; Holst JJ; Hornum M; Feldt-Rasmussen B
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2457-66. PubMed ID: 24712563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered Glucagon and GLP-1 Responses to Oral Glucose in Children and Adolescents With Obesity and Insulin Resistance.
    Stinson SE; Fernández de Retana Alzola I; Brünner Hovendal ED; Lund MAV; Fonvig CE; Holm LA; Jonsson AE; Frithioff-Bøjsøe C; Christiansen M; Pedersen O; Ängquist L; Sørensen TIA; Holst JJ; Hartmann B; Holm JC; Hansen T
    J Clin Endocrinol Metab; 2024 May; 109(6):1590-1600. PubMed ID: 38087928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males.
    Zilstorff DB; Richter MM; Hannibal J; Jørgensen HL; Sennels HP; Wewer Albrechtsen NJ
    BMC Endocr Disord; 2024 Mar; 24(1):38. PubMed ID: 38481208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease.
    Yamaoka-Tojo M; Tojo T; Takahira N; Matsunaga A; Aoyama N; Masuda T; Izumi T
    Cardiovasc Diabetol; 2010 May; 9():17. PubMed ID: 20470376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review.
    Mima A; Nomura A; Fujii T
    Biomed Pharmacother; 2023 Sep; 165():115032. PubMed ID: 37331253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preanalytical impact on the accuracy of measurements of glucagon, GLP-1 and GIP in clinical trials.
    Rasmussen C; Richter MM; Jensen NJ; Heinz N; Hartmann B; Holst JJ; Kjeldsen SAS; Wewer Albrechtsen NJ
    Scand J Clin Lab Invest; 2023 Dec; 83(8):591-598. PubMed ID: 38127365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes.
    Skov-Jeppesen K; Christiansen CB; Hansen LS; Windeløv JA; Hedbäck N; Gasbjerg LS; Hindsø M; Svane MS; Madsbad S; Holst JJ; Rosenkilde MM; Hartmann B
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1773-1780. PubMed ID: 38217866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders.
    Li Y; Vaughan KL; Wang Y; Yu SJ; Bae EK; Tamargo IA; Kopp KO; Tweedie D; Chiang CC; Schmidt KT; Lahiri DK; Tones MA; Zaleska MM; Hoffer BJ; Mattison JA; Greig NH
    Geroscience; 2024 Oct; 46(5):4397-4414. PubMed ID: 38532069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of a High-Carbohydrate versus a High-Fat Shake on Biomarkers of Metabolism and Glycemic Control When Used to Interrupt a 38-h Fast: A Randomized Crossover Study.
    Deru LS; Gipson EZ; Hales KE; Bikman BT; Davidson LE; Horne BD; LeCheminant JD; Tucker LA; Bailey BW
    Nutrients; 2024 Jan; 16(1):. PubMed ID: 38201992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired incretin homeostasis in non-diabetic moderate-severe CKD.
    Ahmadi A; Gamboa J; Norman JE; Enkhmaa B; Tucker M; Bennett BJ; Zelnick LR; Fan S; Berglund LF; Ikizler TA; de Boer IH; Cummings BP; Roshanravan B
    medRxiv; 2023 Dec; ():. PubMed ID: 38196612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of native glucose-dependent insulinotropic polypeptide in humans.
    Helsted MM; Schaltz NL; Gasbjerg LS; Christensen MB; Vilsbøll T; Knop FK
    Peptides; 2024 Jul; 177():171214. PubMed ID: 38615716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thioamide Substitution Selectively Modulates Proteolysis and Receptor Activity of Therapeutic Peptide Hormones.
    Chen X; Mietlicki-Baase EG; Barrett TM; McGrath LE; Koch-Laskowski K; Ferrie JJ; Hayes MR; Petersson EJ
    J Am Chem Soc; 2017 Nov; 139(46):16688-16695. PubMed ID: 29130686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of glucagon-like peptide 1 and glucagon in human plasma.
    Wewer Albrechtsen NJ; Bak MJ; Hartmann B; Christensen LW; Kuhre RE; Deacon CF; Holst JJ
    Endocr Connect; 2015 Mar; 4(1):50-7. PubMed ID: 25596009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration.
    Ammann M; Santol J; Pereyra D; Kalchbrenner T; Wuerger T; Laengle J; Smoot RL; Hulla W; Laengle F; Starlinger P
    Sci Rep; 2023 Sep; 13(1):15980. PubMed ID: 37749369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heightened Vigilance Needed When Patients Are Prescribed GLP-1 and GIP Agonists.
    Johnson TA; Incze MA; Silverstein WK
    JAMA Intern Med; 2024 Aug; ():. PubMed ID: 39102248
    [No Abstract]   [Full Text] [Related]  

  • 16. The potential for renoprotection with incretin-based drugs.
    Tanaka T; Higashijima Y; Wada T; Nangaku M
    Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.
    Scheen AJ
    Clin Pharmacokinet; 2015 Jan; 54(1):1-21. PubMed ID: 25331711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow.
    Jensen EP; Poulsen SS; Kissow H; Holstein-Rathlou NH; Deacon CF; Jensen BL; Holst JJ; Sorensen CM
    Am J Physiol Renal Physiol; 2015 Apr; 308(8):F867-77. PubMed ID: 25656368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitors in progressive kidney disease.
    Makino Y; Fujita Y; Haneda M
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):67-73. PubMed ID: 25415611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients.
    Jørgensen MB; Idorn T; Knop FK; Holst JJ; Hornum M; Feldt-Rasmussen B
    Nephrol Dial Transplant; 2015 Mar; 30(3):513-20. PubMed ID: 25319937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.